Global Psychoactive Substances Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR102405428

Publication Date:

October 9, 2024

Pages:

106

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Psychoactive Substances market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The publisher report includes an overview of the development of the Psychoactive Substances industry chain, the market status of Cancer (Stimulants, Cannabinoids), Neuropathic Disorders (Stimulants, Cannabinoids), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Psychoactive Substances.
Regionally, the report analyzes the Psychoactive Substances markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Psychoactive Substances market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Psychoactive Substances market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Psychoactive Substances industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Stimulants, Cannabinoids).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Psychoactive Substances market.
Regional Analysis: The report involves examining the Psychoactive Substances market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Psychoactive Substances market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Psychoactive Substances:
Company Analysis: Report covers individual Psychoactive Substances players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Psychoactive Substances This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Cancer, Neuropathic Disorders).
Technology Analysis: Report covers specific technologies relevant to Psychoactive Substances. It assesses the current state, advancements, and potential future developments in Psychoactive Substances areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Psychoactive Substances market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Psychoactive Substances market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Stimulants
Cannabinoids
Hallucinogens
Depressants
Market segment by Application
Cancer
Neuropathic Disorders
Spasticity
Market segment by players, this report covers
Zynerba Pharmaceuticals
GW Pharmaceuticals PLC.
Enecta.
Teewinot Life Sciences
GD Pharma
Cape Bouvard Technologies Pty Ltd
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Alpha-CAT
Tilray
Cyrelian Pty Ltd.
MedReleaf Australia
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Psychoactive Substances product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Psychoactive Substances, with revenue, gross margin and global market share of Psychoactive Substances from 2019 to 2024.
Chapter 3, the Psychoactive Substances competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Psychoactive Substances market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Psychoactive Substances.
Chapter 13, to describe Psychoactive Substances research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Product Overview and Scope of Psychoactive Substances
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Psychoactive Substances by Type
1.3.1 Overview: Global Psychoactive Substances Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Psychoactive Substances Consumption Value Market Share by Type in 2023
1.3.3 Stimulants
1.3.4 Cannabinoids
1.3.5 Hallucinogens
1.3.6 Depressants
1.4 Global Psychoactive Substances Market by Application
1.4.1 Overview: Global Psychoactive Substances Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Cancer
1.4.3 Neuropathic Disorders
1.4.4 Spasticity
1.5 Global Psychoactive Substances Market Size & Forecast
1.6 Global Psychoactive Substances Market Size and Forecast by Region
1.6.1 Global Psychoactive Substances Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Psychoactive Substances Market Size by Region, (2019-2030)
1.6.3 North America Psychoactive Substances Market Size and Prospect (2019-2030)
1.6.4 Europe Psychoactive Substances Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Psychoactive Substances Market Size and Prospect (2019-2030)
1.6.6 South America Psychoactive Substances Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Psychoactive Substances Market Size and Prospect (2019-2030)
2 Company Profiles
2.1 Zynerba Pharmaceuticals
2.1.1 Zynerba Pharmaceuticals Details
2.1.2 Zynerba Pharmaceuticals Major Business
2.1.3 Zynerba Pharmaceuticals Psychoactive Substances Product and Solutions
2.1.4 Zynerba Pharmaceuticals Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Zynerba Pharmaceuticals Recent Developments and Future Plans
2.2 GW Pharmaceuticals PLC.
2.2.1 GW Pharmaceuticals PLC. Details
2.2.2 GW Pharmaceuticals PLC. Major Business
2.2.3 GW Pharmaceuticals PLC. Psychoactive Substances Product and Solutions
2.2.4 GW Pharmaceuticals PLC. Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GW Pharmaceuticals PLC. Recent Developments and Future Plans
2.3 Enecta.
2.3.1 Enecta. Details
2.3.2 Enecta. Major Business
2.3.3 Enecta. Psychoactive Substances Product and Solutions
2.3.4 Enecta. Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Enecta. Recent Developments and Future Plans
2.4 Teewinot Life Sciences
2.4.1 Teewinot Life Sciences Details
2.4.2 Teewinot Life Sciences Major Business
2.4.3 Teewinot Life Sciences Psychoactive Substances Product and Solutions
2.4.4 Teewinot Life Sciences Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Teewinot Life Sciences Recent Developments and Future Plans
2.5 GD Pharma
2.5.1 GD Pharma Details
2.5.2 GD Pharma Major Business
2.5.3 GD Pharma Psychoactive Substances Product and Solutions
2.5.4 GD Pharma Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 GD Pharma Recent Developments and Future Plans
2.6 Cape Bouvard Technologies Pty Ltd
2.6.1 Cape Bouvard Technologies Pty Ltd Details
2.6.2 Cape Bouvard Technologies Pty Ltd Major Business
2.6.3 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product and Solutions
2.6.4 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Cape Bouvard Technologies Pty Ltd Recent Developments and Future Plans
2.7 AusCann Group Holdings Pty Ltd.
2.7.1 AusCann Group Holdings Pty Ltd. Details
2.7.2 AusCann Group Holdings Pty Ltd. Major Business
2.7.3 AusCann Group Holdings Pty Ltd. Psychoactive Substances Product and Solutions
2.7.4 AusCann Group Holdings Pty Ltd. Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 AusCann Group Holdings Pty Ltd. Recent Developments and Future Plans
2.8 Cannabics Pharmaceuticals Inc.
2.8.1 Cannabics Pharmaceuticals Inc. Details
2.8.2 Cannabics Pharmaceuticals Inc. Major Business
2.8.3 Cannabics Pharmaceuticals Inc. Psychoactive Substances Product and Solutions
2.8.4 Cannabics Pharmaceuticals Inc. Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Cannabics Pharmaceuticals Inc. Recent Developments and Future Plans
2.9 Alpha-CAT
2.9.1 Alpha-CAT Details
2.9.2 Alpha-CAT Major Business
2.9.3 Alpha-CAT Psychoactive Substances Product and Solutions
2.9.4 Alpha-CAT Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Alpha-CAT Recent Developments and Future Plans
2.10 Tilray
2.10.1 Tilray Details
2.10.2 Tilray Major Business
2.10.3 Tilray Psychoactive Substances Product and Solutions
2.10.4 Tilray Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Tilray Recent Developments and Future Plans
2.11 Cyrelian Pty Ltd.
2.11.1 Cyrelian Pty Ltd. Details
2.11.2 Cyrelian Pty Ltd. Major Business
2.11.3 Cyrelian Pty Ltd. Psychoactive Substances Product and Solutions
2.11.4 Cyrelian Pty Ltd. Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Cyrelian Pty Ltd. Recent Developments and Future Plans
2.12 MedReleaf Australia
2.12.1 MedReleaf Australia Details
2.12.2 MedReleaf Australia Major Business
2.12.3 MedReleaf Australia Psychoactive Substances Product and Solutions
2.12.4 MedReleaf Australia Psychoactive Substances Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 MedReleaf Australia Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Psychoactive Substances Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Psychoactive Substances by Company Revenue
3.2.2 Top 3 Psychoactive Substances Players Market Share in 2023
3.2.3 Top 6 Psychoactive Substances Players Market Share in 2023
3.3 Psychoactive Substances Market: Overall Company Footprint Analysis
3.3.1 Psychoactive Substances Market: Region Footprint
3.3.2 Psychoactive Substances Market: Company Product Type Footprint
3.3.3 Psychoactive Substances Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Psychoactive Substances Consumption Value and Market Share by Type (2019-2024)
4.2 Global Psychoactive Substances Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
5.1 Global Psychoactive Substances Consumption Value Market Share by Application (2019-2024)
5.2 Global Psychoactive Substances Market Forecast by Application (2025-2030)
6 North America
6.1 North America Psychoactive Substances Consumption Value by Type (2019-2030)
6.2 North America Psychoactive Substances Consumption Value by Application (2019-2030)
6.3 North America Psychoactive Substances Market Size by Country
6.3.1 North America Psychoactive Substances Consumption Value by Country (2019-2030)
6.3.2 United States Psychoactive Substances Market Size and Forecast (2019-2030)
6.3.3 Canada Psychoactive Substances Market Size and Forecast (2019-2030)
6.3.4 Mexico Psychoactive Substances Market Size and Forecast (2019-2030)
7 Europe
7.1 Europe Psychoactive Substances Consumption Value by Type (2019-2030)
7.2 Europe Psychoactive Substances Consumption Value by Application (2019-2030)
7.3 Europe Psychoactive Substances Market Size by Country
7.3.1 Europe Psychoactive Substances Consumption Value by Country (2019-2030)
7.3.2 Germany Psychoactive Substances Market Size and Forecast (2019-2030)
7.3.3 France Psychoactive Substances Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Psychoactive Substances Market Size and Forecast (2019-2030)
7.3.5 Russia Psychoactive Substances Market Size and Forecast (2019-2030)
7.3.6 Italy Psychoactive Substances Market Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Psychoactive Substances Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Psychoactive Substances Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Psychoactive Substances Market Size by Region
8.3.1 Asia-Pacific Psychoactive Substances Consumption Value by Region (2019-2030)
8.3.2 China Psychoactive Substances Market Size and Forecast (2019-2030)
8.3.3 Japan Psychoactive Substances Market Size and Forecast (2019-2030)
8.3.4 South Korea Psychoactive Substances Market Size and Forecast (2019-2030)
8.3.5 India Psychoactive Substances Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Psychoactive Substances Market Size and Forecast (2019-2030)
8.3.7 Australia Psychoactive Substances Market Size and Forecast (2019-2030)
9 South America
9.1 South America Psychoactive Substances Consumption Value by Type (2019-2030)
9.2 South America Psychoactive Substances Consumption Value by Application (2019-2030)
9.3 South America Psychoactive Substances Market Size by Country
9.3.1 South America Psychoactive Substances Consumption Value by Country (2019-2030)
9.3.2 Brazil Psychoactive Substances Market Size and Forecast (2019-2030)
9.3.3 Argentina Psychoactive Substances Market Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Psychoactive Substances Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Psychoactive Substances Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Psychoactive Substances Market Size by Country
10.3.1 Middle East & Africa Psychoactive Substances Consumption Value by Country (2019-2030)
10.3.2 Turkey Psychoactive Substances Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Psychoactive Substances Market Size and Forecast (2019-2030)
10.3.4 UAE Psychoactive Substances Market Size and Forecast (2019-2030)
11 Market Dynamics
11.1 Psychoactive Substances Market Drivers
11.2 Psychoactive Substances Market Restraints
11.3 Psychoactive Substances Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Psychoactive Substances Industry Chain
12.2 Psychoactive Substances Upstream Analysis
12.3 Psychoactive Substances Midstream Analysis
12.4 Psychoactive Substances Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Zynerba Pharmaceuticals
GW Pharmaceuticals PLC.
Enecta.
Teewinot Life Sciences
GD Pharma
Cape Bouvard Technologies Pty Ltd
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Alpha-CAT
Tilray
Cyrelian Pty Ltd.
MedReleaf Australia

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂